Literature DB >> 22707562

Therapeutic administration of IL-11 exhibits the postconditioning effects against ischemia-reperfusion injury via STAT3 in the heart.

Masanori Obana1, Kaori Miyamoto, Shiho Murasawa, Tomohiko Iwakura, Akiko Hayama, Tomomi Yamashita, Momoko Shiragaki, Shohei Kumagai, Akimitsu Miyawaki, Kana Takewaki, Goro Matsumiya, Makiko Maeda, Minoru Yoshiyama, Hiroyuki Nakayama, Yasushi Fujio.   

Abstract

Activation of cardiac STAT3 by IL-6 cytokine family contributes to cardioprotection. Previously, we demonstrated that IL-11, an IL-6 cytokine family, has the therapeutic potential to prevent adverse cardiac remodeling after myocardial infarction; however, it remains to be elucidated whether IL-11 exhibits postconditioning effects. To address the possibility that IL-11 treatment improves clinical outcome of recanalization therapy against acute myocardial infarction, we examined its postconditioning effects on ischemia/reperfusion (I/R) injury. C57BL/6 mice were exposed to ischemia (30 min) and reperfusion (24 h), and IL-11 was intravenously administered at the start of reperfusion. I/R injury mediated the activation of STAT3, which was enhanced by IL-11 administration. IL-11 treatment reduced I/R injury, analyzed by triphenyl tetrazolium chloride staining [PBS, 46.7 ± 14.4%; IL-11 (20 μg/kg), 28.6 ± 7.5% in the ratio of infarct to risk area]. Moreover, echocardiographic and hemodynamic analyses clarified that IL-11 treatment preserved cardiac function after I/R. Terminal deoxynucleotide transferase-mediated dUTP nick-end labeling staining revealed that IL-11 reduced the frequency of apoptotic cardiomyocytes after I/R. Interestingly, IL-11 reduced superoxide production assessed by in situ dihydroethidium fluorescence analysis, accompanied by the increased expression of metallothionein 1 and 2, reactive oxygen species (ROS) scavengers. Importantly, with the use of cardiac-specific STAT3 conditional knockout (STAT3 CKO) mice, it was revealed that cardiac-specific ablation of STAT3 abrogated IL-11-mediated attenuation of I/R injury. Finally, IL-11 failed to suppress the ROS production after I/R in STAT3 CKO mice. IL-11 administration exhibits the postconditioning effects through cardiac STAT3 activation, suggesting that IL-11 has the clinical therapeutic potential to prevent I/R injury in heart.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22707562     DOI: 10.1152/ajpheart.00060.2012

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  21 in total

1.  Nitroxide-enhanced MRI of cardiovascular oxidative stress.

Authors:  Soham A Shah; Sophia X Cui; Christopher D Waters; Soichi Sano; Ying Wang; Heather Doviak; Jonathan Leor; Kenneth Walsh; Brent A French; Frederick H Epstein
Journal:  NMR Biomed       Date:  2020-07-09       Impact factor: 4.044

2.  Exogenous IL-19 attenuates acute ischaemic injury and improves survival in male mice with myocardial infarction.

Authors:  Weishuai An; Yongsheng Yu; Yuefan Zhang; Zhigang Zhang; Yunhua Yu; Xianxian Zhao
Journal:  Br J Pharmacol       Date:  2019-01-08       Impact factor: 8.739

3.  Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone Mass.

Authors:  Emma C Walker; Rachelle W Johnson; Yifang Hu; Holly J Brennan; Ingrid J Poulton; Jian-Guo Zhang; Brendan J Jenkins; Gordon K Smyth; Nicos A Nicola; Natalie A Sims
Journal:  J Biol Chem       Date:  2016-08-18       Impact factor: 5.157

Review 4.  Emerging therapeutic targets for cardiac hypertrophy.

Authors:  Alexander J Winkle; Drew M Nassal; Rebecca Shaheen; Evelyn Thomas; Shivangi Mohta; Daniel Gratz; Seth H Weinberg; Thomas J Hund
Journal:  Expert Opin Ther Targets       Date:  2022-01-27       Impact factor: 6.902

5.  Four cases of investigational therapy with interleukin-11 against acute myocardial infarction.

Authors:  Masashi Nakagawa; Yasuko Owada; Yasukatsu Izumi; Shinichi Nonin; Kenichi Sugioka; Daisaku Nakatani; Shinichi Iwata; Kazuki Mizutani; Satoshi Nishimura; Asahiro Ito; Suwako Fujita; Takashi Daimon; Yoshiki Sawa; Masanori Asakura; Makiko Maeda; Yasushi Fujio; Minoru Yoshiyama
Journal:  Heart Vessels       Date:  2016-01-21       Impact factor: 2.037

6.  The cardioprotective effect of interleukin-11 against ischemia-reperfusion injury in a heart donor model.

Authors:  Yusaku Tamura; Hiroki Kohno; Tomomi Mohri; Yasushi Fujio; Goro Matsumiya
Journal:  Ann Cardiothorac Surg       Date:  2018-01

7.  Serum CD121a (Interleukin 1 Receptor, Type I): A Potential Novel Inflammatory Marker for Coronary Heart Disease.

Authors:  Zhengxia Liu; Mengyao Zhang; Jin Wu; Ping Zhou; Ying Liu; Yucheng Wu; Yujiao Yang; Xiang Lu
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

8.  2-aminoethoxydiphenyl borate provides an anti-oxidative effect and mediates cardioprotection during ischemia reperfusion in mice.

Authors:  Hirofumi Morihara; Masanori Obana; Shota Tanaka; Ikki Kawakatsu; Daisuke Tsuchiyama; Shota Mori; Hiroshi Suizu; Akiko Ishida; Rumi Kimura; Izuru Tsuchimochi; Makiko Maeda; Takehiko Yoshimitsu; Yasushi Fujio; Hiroyuki Nakayama
Journal:  PLoS One       Date:  2017-12-21       Impact factor: 3.240

9.  SOCS3 deficiency in cardiomyocytes elevates sensitivity of ischemic preconditioning that synergistically ameliorates myocardial ischemia reperfusion injury.

Authors:  Shoichiro Nohara; Mai Yamamoto; Hideo Yasukawa; Takanobu Nagata; Jinya Takahashi; Koutatsu Shimozono; Toshiyuki Yanai; Tomoko Sasaki; Kota Okabe; Tatsuhiro Shibata; Daiki Akagaki; Kazutoshi Mawatari; Yoshihiro Fukumoto
Journal:  PLoS One       Date:  2021-07-22       Impact factor: 3.240

Review 10.  Emerging therapeutic targets for cardiac arrhythmias: role of STAT3 in regulating cardiac fibroblast function.

Authors:  Nehal J Patel; Drew M Nassal; Daniel Gratz; Thomas J Hund
Journal:  Expert Opin Ther Targets       Date:  2020-11-23       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.